South San Francisco, CA — October 10, 2024 — Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
Dupixent Approved in the US as the First-Ever Biologic...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive...
FDA Approves Cobenfy (xanomeline and trospium...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.